Details:
Under the terms of the arrangement, ST will be responsible for all commercial, medical, regulatory and distribution activities for oregovomab in its key territories of Australia, New Zealand, Singapore, Thailand, Vietnam, Brunei and Malaysia.
Lead Product(s): Oregovomab,Carboplatin,Paclitaxel
Therapeutic Area: Oncology Product Name: MAb-B43.13
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: CanariaBio
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement October 12, 2023
Details:
TLX250-CDx (89Zr-DFO-girentuximab) PET/CT imaging has the potential to improve patient care by serving as a “molecular biopsy” that could be used to guide surveillance, further imaging, or biopsy across all stages of disease.
Lead Product(s): 89Zr-DFO-girentuximab
Therapeutic Area: Oncology Product Name: TLX250-CDx
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 09, 2023
Details:
The exclusive worldwide licence will allow Telix to repurpose LY3012207 (olaratumab) as a targeting agent for radiopharmaceutical imaging and therapy of cancer.
Lead Product(s): Olaratumab,Doxorubicin Hydrochloride
Therapeutic Area: Oncology Product Name: LY3012207
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Eli Lilly
Deal Size: $230.0 million Upfront Cash: $5.0 million
Deal Type: Licensing Agreement April 10, 2022
Details:
This agreement further enhances Telix’s existing 177Lu supplier network, by immediately commence supply for use in clinical trials of Telix’s therapeutic candidates TLX591 (177Lu-rosopatamab for advanced prostate cancer) and TLX250 (177Lu-girentuximab for kidney cancer).
Lead Product(s): 177Lu-rosopatamab
Therapeutic Area: Oncology Product Name: TLX591
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Eckert & Ziegler Strahlen
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement February 09, 2022
Details:
The ProstACT study builds on an already significant body of clinical data for TLX591 (177Lu-DOTA-rosopatamab), which has potential to transform patient outcomes across the full prostate cancer treatment journey.
Lead Product(s): 177Lu-DOTA-rosopatamab
Therapeutic Area: Oncology Product Name: TLX591
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 27, 2022
Details:
The Phase III “ProstACT” trial will compare standard of care therapy alone versus standard of care therapy plus TLX591 in patients with PSMA-expressing mCRPC, experiencing disease progression following prior treatment with a novel androgen axis drug.
Lead Product(s): 177Lu-DOTA-rosopatamab
Therapeutic Area: Oncology Product Name: TLX591
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 10, 2021
Details:
Lurbinectedin has received priority review under the FDA's accelerated approval pathway. Data from a key Phase 2 study of the drug Lurbinectedin demonstrated a clinically meaningful advantage over current standard of care in patients in second-line SCLC therapy.
Lead Product(s): Lurbinectedin,Doxorubicin Hydrochloride
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 03, 2020